Janus kinase inhibitors are of limited use in refractory JIA-associated uveitis: retrospective data from a tertiary uveitis center
Open Access
- 11 July 2026
- journal article
- research article
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 24 (1) , 45
Abstract
Background: Juvenile idiopathic arthritis-associated uveitis (JIAU) frequently follows a chronic and complicated course. Janus kinase inhibitors (JAKi) represent a promising new therapeutic option. Methods: Retrospective monocentric analysis of 20 children with chronic anterior JIAU treated with tofacitinib ( n = 18), baricitinib ( n = 1) or upadacitinib ( n = 1). Outcome measures: uveitis or arthritis inactivity at any time during follow-up, recurrences after achieving inactivity, sparing of medication, occurrence of new ocular complications, resolution of preexisting macular edema. Results: All patients had received methotrexate prior to baseline, and at least two biologics had been ineffective in 18/20 patients. Whilst receiving JAKi medication, uveitis was inactive in eight patients (anterior chamber cell count < 0.5+) at any time during follow-up (mean 9.2 ± 3.3 months), but uveitis relapsed in 6 of them subsequently. In 7 patients, treatment was terminated after ≤ 1 year due to inadequate response of ocular inflammation. During follow-up, new uveitis-related complications occurred in 7 patients (9 eyes), the most frequent were macular edema (8 eyes of 7 patients), and ocular hypertension (5 eyes of 3 patients). Reduction of concomitant systemic medication was possible in 3/14 patients. Any reduction of topical steroids during follow-up was possible in 24/30 eyes, and 23/30 eyes received a lower dose at the last follow-up than they did at baseline. Conclusions: Our data show limited effectiveness of JAKi treatment in patients with chronic DMARD-refractory JIAU. The number of patients in whom uveitis quiescence could be observed was low, as was the possibility for reduction of concomitant medication, and the relapse rate was high. Clinical trial number: Not applicable.Keywords
All Related Versions
Funding Information
- Universitätsklinikum Essen
This publication has 19 references indexed in Scilit:
- JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitisClinical Rheumatology, 2020
- Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic ArthritisOcular Immunology and Inflammation, 2019
- 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated UveitisArthritis Care & Research, 2019
- Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiativeAnnals of the Rheumatic Diseases, 2018
- Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensusRheumatology International, 2015
- Review for Disease of the Year: Epidemiology of Juvenile Idiopathic Arthritis and its Associated Uveitis: The Probable Risk FactorsOcular Immunology and Inflammation, 2013
- Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritisRheumatology International, 2011
- Tumour necrosis factor α inhibitors in the treatment of childhood uveitisRheumatology, 2006
- Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International WorkshopAmerican Journal of Ophthalmology, 2005
- International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.2004